Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.4
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 26248159
Kovacs L, et al. (2016) Activation of Calpain-2 by Mediators in Pulmonary Vascular Remodeling of Pulmonary Arterial Hypertension. Am J Respir Cell Mol Biol 54, 384-93 26248159
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S50-p - CAPN2 (human)
Modsite: GTLFQDPsFPAIPSA SwissProt Entrez-Gene
Orthologous residues
CAPN2 (human): S50‑p, CAPN2 iso2 (human): , CAPN2 (mouse): S50‑p, CAPN2 (rat): S50‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, mass spectrometry, mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'muscle, smooth'-pulmonary artery, HEK293T (epithelial), PASM
Cellular systems studied:  cell lines, tissue
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PDGF increase
5-HT increase
H2O2 increase
endothelin increase
IL-6 increase
PD98059 PDGF inhibit treatment-induced increase
fostriecin PDGF no effect upon treatment-induced increase
Downstream Regulation
Effect of modification (function):  activity, induced
Associated Diseases
Diseases Alterations Comments
PAH increased

S369-p - CAPN2 (human)
Modsite: DGNWRRGstAGGCRN SwissProt Entrez-Gene
Orthologous residues
CAPN2 (human): S369‑p, CAPN2 iso2 (human): S291‑p, CAPN2 (mouse): S369‑p, CAPN2 (rat): S369‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, mass spectrometry, mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'muscle, smooth'-pulmonary artery, HEK293T (epithelial), PASM
Cellular systems studied:  cell lines, tissue
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PDGF decrease
5-HT decrease
H2O2 decrease
endothelin decrease
IL-6 decrease
PD98059 PDGF no effect upon treatment-induced decrease
fostriecin PDGF inhibit treatment-induced decrease
Associated Diseases
Diseases Alterations Comments
PAH decreased

S50-p - CAPN2 (mouse)
Modsite: GALFQDPsFPALPSS SwissProt Entrez-Gene
Orthologous residues
CAPN2 (human): S50‑p, CAPN2 iso2 (human): , CAPN2 (mouse): S50‑p, CAPN2 (rat): S50‑p
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK1 (human) pharmacological inhibitor of upstream enzyme

S369-p - CAPN2 (mouse)
Modsite: DGNWRRGstAGGCRN SwissProt Entrez-Gene
Orthologous residues
CAPN2 (human): S369‑p, CAPN2 iso2 (human): S291‑p, CAPN2 (mouse): S369‑p, CAPN2 (rat): S369‑p